Malignant spinal cord compression is an oncologic emergency caused by epidural tumor extension compressing the dural sac and its contents, affecting approximately 2–5% of cancer patients and requiring immediate recognition and intervention to preserve neurological function. [1-3] The thoracic spine is involved in ~60% of cases, lumbar in ~25%, and cervical in ~15%, with multiple noncontiguous levels found in up to one-third of patients. [4-5]
The following NCCN algorithm outlines the workup and treatment approach:
1. History
- Back pain is the presenting symptom in 83–96% of patients and may precede neurologic deficits by weeks [7-9]
- Characterize pain: local (axial, over the affected vertebra), radicular (dermatomal band-like), or referred (cervical lesions → midscapular; thoracic → hip/lumbosacral; lumbosacral → thoracic) [9]
- Pain often worse when supine and causes nocturnal awakening — a distinguishing feature from degenerative disease [4]
- Pain exacerbated by Valsalva, coughing, sneezing, or straining suggests epidural involvement
- Progressive weakness, gait difficulty, sensory changes (numbness, paresthesias), and bowel/bladder dysfunction (urinary retention, constipation, incontinence) [2][10]
- Tempo of onset: gradual over days to weeks is typical, but acute collapse with sudden paraplegia can occur with pathologic fracture [3]
- Ask about known cancer history, recent weight loss, prior radiation to the spine, and current systemic therapy
2. Alarm Features
- Rapidly progressive motor weakness — the rate of onset is the strongest predictor of irreversibility [1][11]
- Bowel or bladder dysfunction (urinary retention with overflow incontinence is pathognomonic for cauda equina syndrome; 90% sensitivity, 95% specificity) [9]
- Saddle anesthesia and decreased anal sphincter tone [9]
- New bilateral lower extremity weakness or inability to ambulate
- Autonomic dysreflexia (cervical/upper thoracic lesions)
- Pain that is unrelenting, progressive, and unresponsive to analgesics
- Paraplegic for >24 hours — surgical benefit diminishes significantly beyond this window [6][11]
3. Medications
- Dexamethasone — initiate immediately upon clinical suspicion:
- NCCN recommended minimum: dexamethasone 4 mg IV every 6 hours (total 16 mg/day) [6]
- Dose range: 10–100 mg bolus; a randomized trial supported high-dose steroids (96 mg bolus) for improved ambulatory outcomes [12-13]
- Higher doses (≥96 mg/day) carry significantly more adverse effects (14% serious AEs vs. 0% with 16 mg/day) [13]
- Taper over 1–2 weeks once definitive treatment initiated [1][6]
- PJP prophylaxis for patients on prolonged steroids (≥4 weeks at dexamethasone ≥3 mg/day equivalent) [6][14]
- PPI or H2 blocker for GI prophylaxis, especially perioperatively or with concurrent NSAIDs/anticoagulation [6]
- Opioid analgesics for pain management; titrate to effect
- Anticoagulation for VTE prophylaxis — patients with SCI and immobility are at high VTE risk [15-16]
- Avoid: medications that may mask neurologic progression; use caution with sedating agents that impair serial neurologic exams
4. Diet
- No specific dietary triggers
- Ensure adequate hydration (steroid-induced hyperglycemia management, prevention of constipation)
- High-fiber diet or stool softeners to prevent constipation (especially with opioid use and immobility)
- Monitor for steroid-induced hyperglycemia — may require diabetic diet modifications
- Calcium and vitamin D supplementation considerations for prolonged steroid use and bone health
5. Review of Systems
- Neurologic: weakness pattern (upper vs. lower motor neuron), sensory level, gait changes, bowel/bladder function
- Musculoskeletal: focal spine tenderness, pain with movement vs. rest
- Constitutional: weight loss, fevers, night sweats (may suggest lymphoma or infection as alternative diagnosis)
- GI: constipation (neurogenic bowel), nausea (from steroids or opioids)
- GU: urinary retention, frequency, incontinence — check postvoid residual
- Respiratory: dyspnea (high cervical lesions may compromise diaphragmatic function; also screen for PE)
- Psychiatric: depression, anxiety related to functional loss and prognosis
6. Collateral History and Family History
- Cancer history is critical — MSCC is the first manifestation of cancer in ~20% of patients (30% for lung cancer) [3][17]
- Prior treatments: radiation to the spine (limits retreatment options), chemotherapy regimens, surgical history
- Baseline functional status and ambulatory ability before symptom onset
- Goals of care and advance directives — essential for treatment planning
- Family history of cancer (may guide workup for unknown primary)
- Social support and home environment (impacts disposition planning)
7. Risk Factors
- Primary tumor type: prostate, breast, and lung cancer each account for 15–20% of cases; lymphoma, renal cell carcinoma, and myeloma each account for 5–10% [3-4][17]
- Known bone metastases — 90% of patients with autopsy-proven prostate cancer have vertebral metastases [17]
- Thoracic spine metastases carry the highest risk of cord compression [5][18]
- Advanced/disseminated cancer with high tumor burden
- Prior episode of MSCC (recurrence rate 7–14%) [17]
- Younger age paradoxically has higher cumulative incidence of MSCC [17]
- Tumors with high bone tropism (prostate, breast, renal, thyroid, lung)
8. Differential Diagnosis
- Epidural abscess — fever, elevated WBC/ESR/CRP, recent procedure or immunosuppression; MRI with ring-enhancing collection [12]
- Pathologic vertebral compression fracture without cord compression — pain without neurologic deficit
- Leptomeningeal disease — multifocal cranial neuropathies, radiculopathies, CSF cytology positive [6]
- Radiation myelopathy — history of prior RT, delayed onset (months to years), typically progressive
- Intramedullary spinal cord metastasis — rare; central cord syndrome pattern
- Transverse myelitis — inflammatory; often post-infectious or autoimmune
- Paraneoplastic myelopathy — subacute; associated antibodies (e.g., anti-amphiphysin)
- Degenerative cervical/lumbar stenosis — chronic, insidious; no cancer history
- Conus medullaris syndrome vs. cauda equina syndrome — distinguish by exam pattern (UMN vs. LMN)
9. Past Medical History
- Known malignancy — type, stage, treatment history, response status
- Prior spinal surgery or radiation (affects treatment options; NCCN notes surgery is especially indicated if previous RT to site) [6]
- Prior episodes of MSCC
- Osteoporosis or osteopenia (affects instrumentation planning)
- Coagulopathy or anticoagulant use (surgical risk)
- Comorbidities affecting surgical candidacy: cardiac, pulmonary, renal disease
- Performance status (KPS/ECOG) — critical for treatment decision-making [6][19]
10. Physical Exam
- Vital signs: hypotension may indicate spinal shock (cervical/upper thoracic); tachycardia may suggest autonomic dysfunction or PE
- Spine: focal tenderness on percussion over the affected vertebra; palpable step-off or deformity
- Motor: systematic strength testing of all myotomes; document motor level; assess gait if possible
- Sensory: identify a sensory level; test pinprick, light touch, proprioception, and vibration
- Reflexes: hyperreflexia and Babinski sign (UMN lesion above conus); hyporeflexia (cauda equina) [4]
- Rectal exam: anal sphincter tone (decreased in cauda equina syndrome), perianal sensation
- Bladder: postvoid residual (absence of PVR virtually excludes cauda equina syndrome — 99.99% NPV) [9]
- Straight leg raise: may reproduce radicular symptoms
- Assess ambulatory status — the single most important prognostic factor; document Frankel grade [10][18]
11. Lab Studies
- CBC: anemia of chronic disease, leukocytosis (infection vs. steroid effect)
- CMP: calcium (hypercalcemia of malignancy), renal function (contrast planning), glucose (steroid monitoring), LFTs
- Coagulation studies: PT/INR, PTT (preoperative and anticoagulation assessment)
- ESR/CRP: elevated in infection (epidural abscess) and malignancy; helps differentiate
- PSA, tumor markers as guided by suspected primary (if unknown primary)
- SPEP/UPEP, free light chains: if myeloma suspected
- Lactate dehydrogenase: if lymphoma suspected
- Type and screen: if surgery anticipated (vascular tumors like renal cell can bleed significantly)
- Blood glucose monitoring: steroid-induced hyperglycemia is common [6]
12. Imaging
- MRI of the entire spine with and without gadolinium — gold standard, sensitivity 44–93%, specificity 90–98% [2][6][20]
- Must image the entire spine: 15–20% of patients have additional lesions at other levels [6]
- Urgent in the setting of neurologic symptoms [6]
- CT myelogram — alternative if MRI is contraindicated (pacemaker, severe claustrophobia) [6]
- Bilsky ESCC grading on MRI: Grade 0 (bone only) → Grade 1a/1b/1c (epidural impingement without cord compression) → Grade 2 (cord compression with CSF visible) → Grade 3 (cord compression without CSF visible); Grades 2–3 = high-grade compression [21-23]
- CT spine without contrast: useful for assessing bony destruction, fracture, instability, and surgical planning
- Systemic staging: CT chest/abdomen/pelvis or whole-body PET-CT for metastatic workup and identification of primary [6]
- Plain radiographs: low sensitivity; should not be used to rule out MSCC [20]
The following figure illustrates the pathoanatomy of epidural cord compression on MRI:
13. Special Tests
- Spinal Instability Neoplastic Score (SINS): validated scoring system assessing location, pain character, bone lesion quality, alignment, vertebral body collapse, and posterolateral element involvement; SINS ≥7 warrants surgical consultation [4][6]
- Bilsky ESCC Scale: grades epidural compression on axial T2 MRI (0–3); guides need for separation surgery vs. RT [21][23]
- Revised Tokuhashi Score: predicts survival to guide surgical decision-making (score 0–8: conservative; 9–11: palliative surgery; 12–15: excisional surgery) [19]
- Modified Bauer Score: prognostic scoring for surgical candidacy [24]
- Frankel/ASIA grading: standardized neurologic assessment (A = complete paraplegia through E = normal) [18-19]
- NOMS framework (Neurologic, Oncologic, Mechanical instability, Systemic disease): comprehensive decision-making algorithm recommended by NCCN [6][21]
- Postvoid residual measurement: bedside assessment for cauda equina syndrome [9]
- Biopsy: if no known primary or remote cancer history, especially before major surgery [6]
14. ECG
- ECG is not a primary diagnostic tool for MSCC but should be obtained as part of preoperative evaluation
- Bradycardia may occur with high cervical/upper thoracic cord compression due to unopposed vagal tone
- Rule out cardiac arrhythmias in patients with autonomic dysfunction
- Evaluate for signs of PE (sinus tachycardia, right heart strain pattern) given high VTE risk in immobilized cancer patients [15-16]
- Baseline ECG important before initiating medications (opioids, antiemetics) that may prolong QTc
15. Assessment
- MSCC is an oncologic and neurologic emergency — time to treatment directly correlates with neurologic outcome [1-2]
- Pretreatment ambulatory status is the single strongest predictor of post-treatment function and survival [10][18][25]
- European Journal of Surgical Oncology[18]
- Severity stratification: stratify patients into (1) immediate surgery candidates, (2) RT candidates, (3) candidates for outpatient management [1]
- Typical presentation: weeks of progressive back pain → radiculopathy → weakness → sensory level → sphincter dysfunction
- Atypical presentations: painless weakness (rare), isolated bladder dysfunction, MSCC as first presentation of cancer (~20%) [3]
- Complications: permanent paraplegia, neurogenic bowel/bladder, VTE (23.4% incidence in SCI despite prophylaxis), pressure injuries, depression [26]
The NCCN treatment algorithm for confirmed spinal cord compression is shown below:
16. Treatment Plan
Immediate stabilization (ED):
- Dexamethasone: 10 mg IV bolus (range 10–100 mg), then 4 mg IV q6h (16 mg/day minimum); taper over 1–2 weeks [6][12-13]
- Spine precautions (logroll, flat positioning) until stability assessed
- Adequate analgesia (opioids as needed)
- Urgent MRI of the entire spine [6]
- Immediate multidisciplinary consultation: spine surgery + radiation oncology [1-2]
Definitive treatment — per NCCN (category 1 for surgery):
- Surgery ± stabilization followed by RT — category 1 evidence for solitary epidural compression by a radioresistant tumor in patients willing to undergo surgery, with life expectancy ≥3 months, and not paraplegic >24 hours [4][6]
- Surgery especially indicated for: spinal instability, no prior cancer diagnosis, rapid neurologic deterioration during RT, prior RT to site, single-level compression [6]
- Separation surgery is a useful technique for spinal metastatic disease [6]
- Primary RT — for radiosensitive tumors, multilevel disease, poor surgical candidates
- Conventional EBRT: 8 Gy/1 fraction, 20 Gy/5 fractions, or 30 Gy/10 fractions [6]
- SBRT preferred for life expectancy ≥3 months (16–24 Gy/1 fraction; 24–30 Gy/3 fractions; 30–40 Gy/5 fractions) [6]
- Single-fraction RT provides equivalent pain control for patients with poor prognosis [6][13]
- Primary systemic therapy — for chemosensitive tumors (lymphoma, myeloma, germ cell, SCLC) in the absence of clinical myelopathy, with close neurologic monitoring [6]
- VTE prophylaxis: LMWH + compression stockings for all immobilized patients [16][23]
- Rehabilitation: early mobilization, physical/occupational therapy, bowel/bladder program [2]
17. Disposition
Admission criteria:
- Any new neurologic deficit (motor weakness, sensory level, sphincter dysfunction)
- Rapidly progressive symptoms
- Need for IV dexamethasone and urgent surgical/RT planning
- Hemodynamic instability or autonomic dysfunction
- Inability to ambulate
Observation (24 hours):
Discharge criteria:
- Ambulatory, stable neurologic exam, pain controlled on oral medications
- Outpatient RT arranged with close follow-up
- Reliable patient with clear return precautions
Specialist consultation triggers:
- Spine surgery: all cases with cord compression, spinal instability (SINS ≥7), or unknown primary requiring biopsy [1][6]
- Radiation oncology: all cases — for RT planning [1-2]
- Medical oncology: systemic therapy planning, goals of care
- Palliative care: symptom management, advance care planning [2]
- Interventional radiology: preoperative embolization for vascular tumors (e.g., renal cell) [6]
18. Follow-Up / Return Precautions
Follow-up imaging (per NCCN):
- Spine MRI/CT 1–3 months after treatment, then every 3–4 months for 1 year, then as clinically indicated [6]
- Postoperative MRI should be delayed ≥2–3 weeks to avoid surgical artifacts [6]
Return precautions — counsel patients to seek immediate care for:
- New or worsening weakness in arms or legs
- New numbness, tingling, or loss of sensation
- Loss of bowel or bladder control
- Worsening or new back pain
- Inability to walk or new gait difficulty
- Falls
Expected course:
- Patients ambulatory at treatment onset: ~75% remain ambulatory at 6 months [8]
- Median survival: 3–6 months overall; longer with favorable histology and retained ambulation [18][27]
- Recurrence at same or different level occurs in 7–14% [17]
- Steroid side effects to monitor: hyperglycemia, GI bleeding, myopathy, infection, adrenal insufficiency on taper [6]
References
1. Initial Management and Disposition of Metastatic Spinal Cord Compression in the Emergency Department: A Review of the Literature. — Singer E, Elsayem A, Nassif T, et al. Annals of Medicine. 2025.
2. Initial Management and Disposition of Metastatic Spinal Cord Compression in the Emergency Department: A Review of the Literature. — Singer E, Elsayem A, Nassif T, et al. Annals of Medicine. 2025.
3. Initial Management and Disposition of Metastatic Spinal Cord Compression in the Emergency Department: A Review of the Literature. — Singer E, Elsayem A, Nassif T, et al. Annals of Medicine. 2025.
4. Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review. — Lawton AJ, Lee KA, Cheville AL, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2019.
5. Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review. — Lawton AJ, Lee KA, Cheville AL, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2019.
6. Metastatic Epidural Spinal Cord Compression. — Cole JS, Patchell RA. The Lancet. Neurology. 2008.
7. Metastatic Epidural Spinal Cord Compression. — Cole JS, Patchell RA. The Lancet. Neurology. 2008.
8. Acute Spinal Cord Compression. — Ropper AE, Ropper AH. The New England Journal of Medicine. 2017.
9. Acute Spinal Cord Compression. — Ropper AE, Ropper AH. The New England Journal of Medicine. 2017.
10. Spinal Cord Compression from Epidural Metastases. — Byrne TN. The New England Journal of Medicine. 1992.
11. Spinal Cord Compression from Epidural Metastases. — Byrne TN. The New England Journal of Medicine. 1992.
12. Central Nervous System Cancers. — Updated 2026-04-24. National Comprehensive Cancer Network.
13. Central Nervous System Cancers. — Updated 2026-04-24. National Comprehensive Cancer Network.
14. Comprehensive Guide to the Diagnosis, Management, and Treatment of Metastatic Spinal Cord Compression Syndrome. — Vega Moreno DA, Reyes Soto G, Lopez-Valdes JC, et al. Surgical Oncology. 2025.
15. Comprehensive Guide to the Diagnosis, Management, and Treatment of Metastatic Spinal Cord Compression Syndrome. — Vega Moreno DA, Reyes Soto G, Lopez-Valdes JC, et al. Surgical Oncology. 2025.
16. Epidural Spinal Cord Compression From Metastatic Tumor: Diagnosis and Treatment. — Gilbert RW, Kim JH, Posner JB. Annals of Neurology. 1978.
17. Epidural Spinal Cord Compression From Metastatic Tumor: Diagnosis and Treatment. — Gilbert RW, Kim JH, Posner JB. Annals of Neurology. 1978.
18. Spinal Cord Compression in Patients With Advanced Metastatic Cancer: “All I Care About Is Walking and Living My Life”. — Abrahm JL, Banffy MB, Harris MB. The Journal of the American Medical Association. 2008.
19. Spinal Cord Compression in Patients With Advanced Metastatic Cancer: “All I Care About Is Walking and Living My Life”. — Abrahm JL, Banffy MB, Harris MB. The Journal of the American Medical Association. 2008.
20. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. — Boussios S, Cooke D, Hayward C, et al. Anticancer Research. 2018.
21. Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. — Boussios S, Cooke D, Hayward C, et al. Anticancer Research. 2018.
22. Predicting Neurologic Recovery After Surgery in Patients With Deficits Secondary to MESCC: Systematic Review. — Laufer I, Zuckerman SL, Bird JE, et al. Spine. 2016.
23. Predicting Neurologic Recovery After Surgery in Patients With Deficits Secondary to MESCC: Systematic Review. — Laufer I, Zuckerman SL, Bird JE, et al. Spine. 2016.
24. Neurological Complications of Systemic Cancer. — Khasraw M, Posner JB. The Lancet. Neurology. 2010.
25. Neurological Complications of Systemic Cancer. — Khasraw M, Posner JB. The Lancet. Neurology. 2010.
26. Interventions for the Treatment of Metastatic Extradural Spinal Cord Compression in Adults. — George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P. The Cochrane Database of Systematic Reviews. 2015.
27. Interventions for the Treatment of Metastatic Extradural Spinal Cord Compression in Adults. — George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P. The Cochrane Database of Systematic Reviews. 2015.
28. External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline. — Alcorn S, Cortés ÁA, Bradfield L, et al. Practical Radiation Oncology. 2024.
29. External Beam Radiation Therapy for Palliation of Symptomatic Bone Metastases: An ASTRO Clinical Practice Guideline. — Alcorn S, Cortés ÁA, Bradfield L, et al. Practical Radiation Oncology. 2024.
30. Exploring Venous Thromboembolism (VTE) Risk in Patients With Acute Spinal Cord Injury (SCI). — Bassa BA, Passos VL, McDonnell J, et al. Injury. 2025.
31. Exploring Venous Thromboembolism (VTE) Risk in Patients With Acute Spinal Cord Injury (SCI). — Bassa BA, Passos VL, McDonnell J, et al. Injury. 2025.
32. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. — Gould MK, Garcia DA, Wren SM, et al. Chest. 2012.
33. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. — Gould MK, Garcia DA, Wren SM, et al. Chest. 2012.
34. Malignant Spinal-Cord Compression. — Prasad D, Schiff D. The Lancet. Oncology. 2005.
35. Malignant Spinal-Cord Compression. — Prasad D, Schiff D. The Lancet. Oncology. 2005.
36. Metastatic Epidural Spinal Cord Compression Approached by MRI: Could It Predict Neurological Peril?. — Beaufort Q, Lefevre V, Cottier JP, et al. European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2025.
37. Metastatic Epidural Spinal Cord Compression Approached by MRI: Could It Predict Neurological Peril?. — Beaufort Q, Lefevre V, Cottier JP, et al. European Journal of Surgical Oncology : The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2025.
38. Determinants of Overall and Readmission-Free Survival in Patients With Metastatic Epidural Spinal Cord Compression. — Pojskić M, Saß B, Bopp MHA, Wilke S, Nimsky C. Cancers. 2024.
39. Determinants of Overall and Readmission-Free Survival in Patients With Metastatic Epidural Spinal Cord Compression. — Pojskić M, Saß B, Bopp MHA, Wilke S, Nimsky C. Cancers. 2024.
40. Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. — Loblaw DA, Perry J, Chambers A, Laperriere NJ. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2005.
41. Systematic Review of the Diagnosis and Management of Malignant Extradural Spinal Cord Compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. — Loblaw DA, Perry J, Chambers A, Laperriere NJ. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2005.
42. An Integrated Multidisciplinary Algorithm for the Management of Spinal Metastases: An International Spine Oncology Consortium Report. — Spratt DE, Beeler WH, de Moraes FY, et al. The Lancet. Oncology. 2017.
43. An Integrated Multidisciplinary Algorithm for the Management of Spinal Metastases: An International Spine Oncology Consortium Report. — Spratt DE, Beeler WH, de Moraes FY, et al. The Lancet. Oncology. 2017.
44. Clinical Results of Minimally Invasive Spine Stabilization for the Management of Metastatic Spinal Tumors Based on the Epidural Spinal Cord Compression Scale. — Uei H, Tokuhashi Y, Maseda M, et al. BioMed Research International. 2018.
45. Clinical Results of Minimally Invasive Spine Stabilization for the Management of Metastatic Spinal Tumors Based on the Epidural Spinal Cord Compression Scale. — Uei H, Tokuhashi Y, Maseda M, et al. BioMed Research International. 2018.
46. Metastatic spinal cord compression: a review of practice and care. — Kilbride L, Cox M, Kennedy CM, Lee SH, Grant R. Journal of Clinical Nursing. 2010.
47. Metastatic spinal cord compression: a review of practice and care. — Kilbride L, Cox M, Kennedy CM, Lee SH, Grant R. Journal of Clinical Nursing. 2010.
48. More Help Than Harm: Surgery for Metastatic Spinal Cord Compression Is Associated With More Favorable Overall Survival Within a Propensity Score Analysis. — Leitner L, Bratschitsch G, Kostwein A, et al. European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2023.
49. More Help Than Harm: Surgery for Metastatic Spinal Cord Compression Is Associated With More Favorable Overall Survival Within a Propensity Score Analysis. — Leitner L, Bratschitsch G, Kostwein A, et al. European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2023.
50. Observation Versus Screening Spinal MRI and Pre-Emptive Treatment for Spinal Cord Compression in Patients With Castration-Resistant Prostate Cancer and Spinal Metastases in the UK (PROMPTS): An Open-Label, Randomised, Controlled, Phase 3 Trial. — Dearnaley D, Hinder V, Hijab A, et al. The Lancet. Oncology. 2022.
51. Observation Versus Screening Spinal MRI and Pre-Emptive Treatment for Spinal Cord Compression in Patients With Castration-Resistant Prostate Cancer and Spinal Metastases in the UK (PROMPTS): An Open-Label, Randomised, Controlled, Phase 3 Trial. — Dearnaley D, Hinder V, Hijab A, et al. The Lancet. Oncology. 2022.
52. The Short- And Long-Term Risk of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Prospective Cohort Study. — Giorgi Pierfranceschi M, Donadini MP, Dentali F, et al. Thrombosis and Haemostasis. 2013.
53. The Short- And Long-Term Risk of Venous Thromboembolism in Patients With Acute Spinal Cord Injury: A Prospective Cohort Study. — Giorgi Pierfranceschi M, Donadini MP, Dentali F, et al. Thrombosis and Haemostasis. 2013.
54. Epidural Spinal Cord Compression. — Spinazzé S, Caraceni A, Schrijvers D. Critical Reviews in Oncology/Hematology. 2005.
55. Epidural Spinal Cord Compression. — Spinazzé S, Caraceni A, Schrijvers D. Critical Reviews in Oncology/Hematology. 2005.